Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012–2014
Thelma E. Tupasi
, Anna Marie Celina G. Garfin, Ekaterina V. Kurbatova, Joan M. Mangan, Ruth Orillaza-Chi, Leilani C. Naval, Glenn I. Balane, Ramon Basilio, Alexander Golubkov, Evelyn S. Joson, Woo-jin Lew, Vivian Lofranco, Mariquita Mantala, Stuart Pancho, and Jesus N. Sarol
Author affiliations: Tropical Disease Foundation, Inc., Makati City, the Philippines (T.E. Tupasi, L.C. Naval, G.I. Balane, E.S. Joson, J.N. Sarol Jr.); Department of Health, Manila, the Philippines (A.M.C.G. Garfin, R. Basilio); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.V. Kurbatova, J.M. Mangan); Philippine Business for Social Progress–Innovations and Multisectoral Partnership to Achieve Control of Tuberculosis Project, Manila (R. Orillaza-Chi); US Agency for International Development (USAID), Washington, DC, USA (A. Golubkov); World Health Organization Philippines, Manila (W.-j. Lew); The Lung Center of the Philippines, Manila (V. Lofranco, S. Pancho); Technical Assistance to the Countries–USAID-funded activity, Manila (M. Mantala)
Figure 2. Social ecologic model used to identify factors influencing loss to follow-up during treatment for multidrug resistant tuberculosis in the Philippines, 2012–2014. Boldface indicates data collected through patient interviews and medical record abstractions. DOTS, directly observed therapy.
Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.